ADAR1 Capital Management »

IsoRay shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of IsoRay (CATX) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in IsoRay

Tip: Access up to 7 years of quarterly data

All positions including IsoRay held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in IsoRay by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $17k 42k 0.40

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Royalty Pharma Shs Class A (RPRX)
Keros Therapeutics (KROS)
Roivant Sciences SHS (ROIV)
Cytokinetics Com New (CYTK)
Arbutus Biopharma (ABUS)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New (MACK)
Cerevel Therapeutics Hldng I (CERE)
Mirati Therapeutics
Merck & Co (MRK)
Ascendis Pharma A/s Sponsored Adr (ASND)
Immunovant (IMVT)
Viking Therapeutics (VKTX)
Protagonist Therapeutics (PTGX)

View all positions for ADAR1 Capital Management

Top funds holding IsoRay

Vanguard Group
Baker Bros. Advisors
AlphaCentric Advisors
Osterweis Capital Management
HighTower Advisors
Perkins Capital Management
Taylor & Morgan Wealth Management
Portland Investment Counsel
Creative Planning
Wealth Effects
Charles Schwab Investment Management
Mariner Wealth Advisors
Bank of New York Mellon
Commonwealth Equity Services
ADAR1 Capital Management

View all funds holding IsoRay